Tag: platinum-resistant
ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...
Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...
Lifastuzumab Vedotin is Well-tolerated + Improves Objective Response Rate in Phase...
Lifastuzumab vedotin, also known as DNIB0600A (RO5541081) and RG-7599, is an antibody-drug conjugate or ADC.
In clinical trials the investigational drug is compared to pegylated...
Study Confirms DMOT4039A Shows Anticancer Activity in Patients with Pancreatic or...
A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) being held May 30 - June 3, 2014 in Chicago, Ill, describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.
